title: New vaccines against tuberculosis.
abstract: The only currently licensed tuberculosis (TB) vaccine, bacille Calmette Guérin, confers incomplete protection against tuberculosis, and is not safe in infants infected with the human immunodeficiency virus. A new, safe vaccine regimen, which better protects against lung disease, is urgently needed to control TB in high-burden countries. Multiple candidate vaccines have shown promise in preclinical studies, and are now entering phase 1 to 2B clinical trials. This article discusses progress in the field and issues surrounding safety, reactogenicity, immunogenicity, and efficacy testing of new TB vaccines.
authors.affiliation: Centre of Vaccinology, CMU, 1 rue Michel-Servet, 1211 Geneva 4, Switzerland University of Geneva, Switzerland. paul.lambert@unige.ch
authors.forename: Paul-Henri
authors.initials: PH
authors.lastname: Lambert
authors.forename: Tony
authors.initials: T
authors.lastname: Hawkridge
authors.forename: Willem A
authors.initials: WA
authors.lastname: Hanekom
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D014376:Tuberculosis / Q000517:prevention & control*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine